Zacks Small Cap Has Bearish Outlook for ABEO FY2027 Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Zacks Small Cap decreased their FY2027 EPS estimates for Abeona Therapeutics in a report issued on Friday, November 14th. Zacks Small Cap analyst D. Bautz now anticipates that the biopharmaceutical company will post earnings per share of $1.91 for the year, down from their prior forecast of $2.15. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.17.

A number of other equities analysts also recently commented on ABEO. Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Abeona Therapeutics in a research report on Monday, October 13th. Oppenheimer raised their price target on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Friday, August 15th. Finally, Weiss Ratings downgraded shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 24th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Abeona Therapeutics Price Performance

Shares of Abeona Therapeutics stock opened at $4.51 on Monday. The business’s fifty day moving average price is $5.30 and its 200 day moving average price is $5.96. Abeona Therapeutics has a twelve month low of $3.93 and a twelve month high of $7.54. The company has a current ratio of 6.73, a quick ratio of 6.65 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $244.40 million, a P/E ratio of 6.44 and a beta of 1.45.

Insider Buying and Selling

In related news, SVP Brendan M. O’malley sold 9,366 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $5.39, for a total transaction of $50,482.74. Following the transaction, the senior vice president directly owned 350,763 shares of the company’s stock, valued at approximately $1,890,612.57. The trade was a 2.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Joseph Walter Vazzano sold 9,035 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $5.39, for a total value of $48,698.65. Following the completion of the transaction, the chief financial officer owned 453,631 shares of the company’s stock, valued at approximately $2,445,071.09. This represents a 1.95% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 78,612 shares of company stock valued at $410,271. Insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Abeona Therapeutics

A number of large investors have recently added to or reduced their stakes in ABEO. Intech Investment Management LLC lifted its holdings in Abeona Therapeutics by 19.6% in the 3rd quarter. Intech Investment Management LLC now owns 25,176 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 4,127 shares in the last quarter. Creative Planning grew its stake in shares of Abeona Therapeutics by 43.0% during the second quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock valued at $81,000 after acquiring an additional 4,305 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new stake in shares of Abeona Therapeutics during the second quarter worth about $25,000. Legal & General Group Plc acquired a new position in shares of Abeona Therapeutics in the second quarter worth about $27,000. Finally, Riverwater Partners LLC lifted its stake in shares of Abeona Therapeutics by 45.6% in the third quarter. Riverwater Partners LLC now owns 15,857 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 4,963 shares in the last quarter. 80.56% of the stock is owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.